Co-Diagnostics Inc. (NASDAQ: CODX) is 1931.95% higher on its value in year-to-date trading and has touched a low of $0.85 and a high of $29.72 in the current 52-week trading range. The CODX stock was last observed hovering at around $18.19 in the recent trading session, with the current loss setting it -0.43% off its average median price target of $35.00 for the next 12 months. It is also 50.67% off the consensus price target high of $36.00 offered by 3 analysts, but current levels are 40.8% higher than the price target low of $30.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $17.76, the stock is -0.06% and 3.06% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.46 million and changing -2.36% at the moment leaves the stock 134.67% off its SMA200. CODX registered 1576.50% gain for a year compared to 6-month gain of 1887.33%. The firm has a 50-day simple moving average (SMA 50) of $17.43 and a 200-day simple moving average (SMA200) of $10.66.
The stock witnessed a 13.83% loss in the last 1 month and extending the period to 3 months gives it a 106.70%, and is -3.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.46% over the week and 8.88% over the month.
Co-Diagnostics Inc. (CODX) has around 27 employees, a market worth around $494.59M and $1.80M in sales. Fwd P/E is 8.89. Distance from 52-week low is 1998.55% and -40.24% from its 52-week high. The company has generated returns on investments over the last 12 months (-346.70%).
Co-Diagnostics Inc. (CODX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Co-Diagnostics Inc. (CODX) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Co-Diagnostics Inc. is expected to release its quarterly report on 08/17/2020 and quarterly earnings per share for the current quarter are estimated at $0.59 with sales reaching $26.45M over the same period.The EPS is expected to grow by 26.40% this year, but quarterly earnings will post 43,365.10% year-over-year. Quarterly sales are estimated to grow 43,983.30% in year-over-year returns.
Co-Diagnostics Inc. (CODX) Top Institutional Holders
30 institutions hold shares in Co-Diagnostics Inc. (CODX), with 6.65M shares held by insiders accounting for 24.21% while institutional investors hold 12.10% of the company’s shares. The shares outstanding are 22.82M, and float is at 20.81M with Short Float at 23.36%. Institutions hold 9.17% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 0.78 million shares valued at $5.92 million. The investor’s holdings represent 2.83% of the CODX Shares outstanding. As of Mar 30, 2020, the second largest holder is Morgan Stanley with 0.37 million shares valued at $2.8 million to account for 1.34% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 0.12 million shares representing 0.44% and valued at over $0.92 million, while Millennium Management LLC holds 0.38% of the shares totaling 0.1 million with a market value of $0.79 million.
Co-Diagnostics Inc. (CODX) Insider Activity
A total of 10 insider transactions have happened at Co-Diagnostics Inc. (CODX) in the last six months, with sales accounting for 6 and purchases happening 4 times. The most recent transaction is an insider sale by SERBIN RICHARD S, the company’s Director. SEC filings show that SERBIN RICHARD S sold 25,000 shares of the company’s common stock on May 28 at a price of $18.02 per share for a total of $0.45 million. Following the sale, the insider now owns 0.0 shares.
Co-Diagnostics Inc. disclosed in a document filed with the SEC on May 26 that Durenard Eugene (Director) sold a total of 25,000 shares of the company’s common stock. The trade occurred on May 26 and was made at $18.26 per share for $0.46 million. Following the transaction, the insider now directly holds 0.0 shares of the CODX stock.
Still, SEC filings show that on May 20, Durenard Eugene (Director) disposed off 25,000 shares at an average price of $18.40 for $0.46 million. The insider now directly holds 0 shares of Co-Diagnostics Inc. (CODX).